Abstract:OBJECTIVETo investigate the use of glucocorticoids in patients with severe community-acquired pneumonia (SCAP) in the intensive care unit (ICU) of Hospitals in Zhejiang Province and to provide a reference for guiding clinical use of SCAP patients.METHODSTo draw up a questionnaire with reference to the Chinese and international guidelines, and to investigate the knowledge of community-acquired pneumonia (CAP) related guidelines and the use of glucocorticoids in patients with SCAP by doctors in hospitals above secondary level in Zhejiang Province by Email. Then the valid questionnaire was analyzed.RESULTSIn June 2016, 340 questionnaires were distributed, and all were returned after 2 months, with 333 of valid; 333 doctors from 45 ICUs in Zhejiang Province participated in the survey. (1) The knowledge of CAP-related guidelines in ICU doctors: 79.58% (265/333) of the doctors had read the CAP guidelines, and those who work over 10 years had a higher reading rate than those with 1-5 years and 6-10 years [93.07% (94/101) vs. 74.00% (111/150), 73.17% (60/82), both P < 0.05]. Post-graduates and above had higher reading rates than undergraduates [85.35% (134/157) vs. 74.43% (131/176), P < 0.05]. Senior doctors had higher reading rates than the junior and intermediate doctors [93.07% (94/101) vs. 71.43% (80/112), 75.83% (91/120), both P < 0.05]. The rate of understanding the clinical application of glucocorticoids was 13.81% (46/333). The doctors who work over 10 years and the seniorshad a relatively high awareness rate, 23.76% (24/101) and 20.79% (21/101) respectively. However, there was no significant difference in the awareness rate between doctors with different degrees and different levels of hospitals. (2) For the use of glucocorticoids in different causes of pneumonia, 44.74% (149/333) of doctors routinely used glucocorticoids in severe viral pneumonia. The proportion of glucocorticoids used in severe bacterial pneumonia, severe fungal pneumonia, severe pneumocystis pneumonia, chronic obstructive pulmonary disease (COPD) and severe pneumonia were 22.82% (76/333), 9.31% (31/333), 22.52% (75/333) and 18.32% (61/333), respectively. (3) The way of glucocorticoid usage: 79.58% (265/333) of doctors chose methylprednisolone, 4.20% (14/333) chose hydrocortisone, 1.20% (4/333) chose dexamethasone, and 15.02% (50/333) had not use glucocorticoids. The proportion of physicians who chose to use glucocorticoids within 24 hours of admission and 1-7 days after admission were 52.65% (149/283) and 47.35% (134/283), respectively. Glucocorticoids were used more in doctors with lower academic qualifications and hospitals within 24 hours. The undergraduate degree was 61.39% (97/158), and the second-grade class hospital was 67.50% (27/40). Among the doctors who chose methylprednisolone, 60.75% (161/265) prescribe the dose ≤ 80 mg/d; 79.15% (224/283) chose the course of ≤ 7 days. The number of years of work, education, professional title and hospital grade had no significant effect on the choice of methylprednisolone and the course of treatment.CONCLUSIONSICU doctors of 45 hospitals in Zhejiang Province have a high degree of heterogeneity in the understanding of the use and guidelines of glucocorticoids in SCAP. It is necessary to strengthen the ICU doctor's study of clinical guidelines at home and abroad and to develop a glucocorticoid use plan according to the specific conditions of patients, so that SCAP patients can benefit more.

Application of glucocorticoids in systemic inflammatory response syndrome

Application of glucocorticoids in children with infectious mononucleosis

The Research and Application of Glucocorticoid in Severe Sepsis and Septic Shock

Safety of high dose inhaled corticosteroids

[Survey on the Use of Glucocorticoids in Severe Community-Acquired Pneumonia in Intensive Care Unit of Forty-Five Hospitals in Zhejiang Province].

Efficacy and Safety of Glucocorticoids in Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Clinical Application of Glucocorticoids in Anti-infection Treatment of Central Nervous System

Application progress of glucocorticoids in the management of refractory cancer pain

Interpretation of Application of Glucocorticoids in Minimally Invasive Interventional Treatment for Pain (chinese Expert Consensus):The Severe Side Effects Induced by Glucocorticoids in Epidural Injection and Its Prevention

Progress of glucocorticoid receptor in severe sepsis and septic shock

Research advances of corticosteroids in treatment of acute exacerbation of chronic obstructive pulmonary disease

Effect of glucocorticoid (GC) in treatment of patients with acute respiratory distress syndrome (ARDS) extra pulmonary infection

Progress of Study on Resistance Mechanism of Glucocorticoid in Childhood Acute Lymphoblastic Leukemia

Efficacy and safety of corticosteroids for septic shock in immunocompromised patients: A cohort study from MIMIC

Why chronic obstructive pulmonary disease patients can get benefit from corticosteroid

[Impact of systemic corticosteroids on the clinical outcomes in patients with severe community-acquired pneumonia: a multi-center retrospective study].

Corticosteroid Administration is Associated with Improved Outcome of Patients Presenting High Inflammatory Cytokine Levels During Septic Shock

Application of Glucocorticoids in Treatment of COVID-19

Effectiveness and Safety of Early Short-Course, Moderate- to High-Dose Glucocorticoids for the Treatment of Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Retrospective Study

Effect and its clinical significance of different dose of glucocorticoids on inflammation mediators in patients with acute exacerbation of chronic obstructive pulmonary diseases

Thirty-Nine Children with Refractory Systemic Juvenile Idiopathic Arthritis Treated by Glucocorticoid